# Takeda

> Takeda is a Japanese, R&D-driven biopharmaceutical company that develops, manufactures and commercializes prescription medicines and vaccines in gastrointestinal and inflammatory disease, rare disease, plasma-derived therapies, oncology, neuroscience and vaccines. Its scale was remade by the 2019 acquisition of Shire; today it sells globally, earns almost half its revenue in the United States and is navigating patent losses by investing in a concentrated late-stage pipeline and external partnerships.

- **Founded:** 1781
- **Headquarters:** Tokyo, Japan
- **Founders:** Chobei Takeda I (Founder and medicine merchant)
- **Team size:** Approximately 50,000 employees worldwide
- **Products:** ENTYVIO (vedolizumab), TAKHZYRO (lanadelumab), QDENGA, FRUZAQLA (fruquintinib), EOHILIA (budesonide oral suspension)
- **Notable:** Survived and transformed across more than two centuries since its 1781 founding in Osaka., Completed the acquisition of Shire in January 2019, creating a global biopharma group with more than US$30 billion in combined annual revenue at closing., Built ENTYVIO into a leading prescribed inflammatory bowel disease brand in the United States, according to company-cited IQVIA patient-share data.

## Products & services

- **ENTYVIO (vedolizumab)** — Gut-selective biologic therapy for adults with moderately to severely active ulcerative colitis or Crohn's disease; formulations and indications vary by market.
- **TAKHZYRO (lanadelumab)** — Preventive treatment for hereditary angioedema attacks.
- **QDENGA** — Live-attenuated tetravalent dengue vaccine available in multiple endemic and travel markets, subject to local recommendations.
- **FRUZAQLA (fruquintinib)** — Oral targeted treatment for previously treated metastatic colorectal cancer in approved markets.
- **EOHILIA (budesonide oral suspension)** — U.S. oral therapy for eosinophilic esophagitis in people aged 11 and older for a 12-week course.
- **LIVTENCITY (maribavir)** — Antiviral treatment for post-transplant cytomegalovirus infection or disease that is refractory to other therapies, with labeling varying by market.
- **Plasma-derived therapies** — Immunoglobulin and albumin portfolios including GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU and FLEXBUMIN, plus treatments for bleeding and rare immune disorders.
- **ORZEYFUL (oveporexton)** — First-in-class orexin receptor 2 agonist approved in China in 2026 for narcolepsy type 1; under review in other markets as of August 2026.

## Achievements

- Survived and transformed across more than two centuries since its 1781 founding in Osaka.
- Completed the acquisition of Shire in January 2019, creating a global biopharma group with more than US$30 billion in combined annual revenue at closing.
- Built ENTYVIO into a leading prescribed inflammatory bowel disease brand in the United States, according to company-cited IQVIA patient-share data.
- Expanded QDENGA to 31 countries by the first half of FY2025.
- Reported positive Phase 3 results and regulatory submissions for multiple late-stage programs during FY2025.
- Received China's 2026 approval for ORZEYFUL, the first approved orexin receptor 2 agonist for narcolepsy type 1 there.

## Latest updates

- **2026-07** — China approved ORZEYFUL (oveporexton) for narcolepsy type 1 in adolescents aged 16 and older and adults.
- **2026-07** — Takeda and the Indonesian government announced a plasma ecosystem collaboration with up to US$30 million in initial investment.
- **2026-06** — Julie Kim formally became representative director, president and CEO after an 18-month succession process.
- **2026-06** — Takeda revised FY2025 reported earnings to recognize a JPY 402.5 billion legal provision related to the AMITIZA antitrust verdict; core FY2025 results and FY2026 guidance were unchanged.
- **2026-05** — Takeda reported FY2025 revenue of JPY 4,505.7 billion, down 1.7% year over year; core operating profit increased 0.8% at actual exchange rates.
- **2026-01** — Takeda licensed Halozyme's ENHANZE technology for potential use with vedolizumab.
- **2025-12** — Takeda closed its strategic oncology partnership with Innovent Biologics.

## Links

- Website: https://www.takeda.com/
- LinkedIn: https://www.linkedin.com/company/takeda-pharmaceuticals/
- Twitter/X: https://twitter.com/takedapharma
- YouTube: https://www.youtube.com/takeda-pharmaceuticals
- Instagram: https://www.instagram.com/takeda_pharmaceuticals/
- Facebook: https://www.facebook.com/takedapharma
- TikTok: https://www.tiktok.com/@takedapharmaceuticals

---

Profile page: https://yespress.io/takeda
Published by YesPress — https://yespress.io
Last updated: 2026-08-13